Cargando…

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals

Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlea, Danielle M, Fee, Laura T, McEnery, Thomas, McElvaney, Noel G, Reeves, Emer P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875399/
https://www.ncbi.nlm.nih.gov/pubmed/29618937
http://dx.doi.org/10.2147/JIR.S156405
_version_ 1783310343682916352
author Dunlea, Danielle M
Fee, Laura T
McEnery, Thomas
McElvaney, Noel G
Reeves, Emer P
author_facet Dunlea, Danielle M
Fee, Laura T
McEnery, Thomas
McElvaney, Noel G
Reeves, Emer P
author_sort Dunlea, Danielle M
collection PubMed
description Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil.
format Online
Article
Text
id pubmed-5875399
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58753992018-04-04 The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals Dunlea, Danielle M Fee, Laura T McEnery, Thomas McElvaney, Noel G Reeves, Emer P J Inflamm Res Review Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil. Dove Medical Press 2018-03-26 /pmc/articles/PMC5875399/ /pubmed/29618937 http://dx.doi.org/10.2147/JIR.S156405 Text en © 2018 Dunlea et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Dunlea, Danielle M
Fee, Laura T
McEnery, Thomas
McElvaney, Noel G
Reeves, Emer P
The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_full The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_fullStr The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_full_unstemmed The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_short The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_sort impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875399/
https://www.ncbi.nlm.nih.gov/pubmed/29618937
http://dx.doi.org/10.2147/JIR.S156405
work_keys_str_mv AT dunleadaniellem theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT feelaurat theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT mcenerythomas theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT mcelvaneynoelg theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT reevesemerp theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT dunleadaniellem impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT feelaurat impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT mcenerythomas impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT mcelvaneynoelg impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
AT reevesemerp impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals